NVAXNovavax, Inc.
10.40USD+12.87%Mkt Cap: 1.71B USDP/E: Last update: 2026-05-26

Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company comme…

Indicators:|

Key Statistics

Company
Market Cap1.71B USD
Enterprise Value981.38M USD
Revenue (TTM)596.34M USD
Gross Profit1.05B USD
Net Income (TTM)440.30M USD
Revenue/Share3.669 USD
Last Price10.40 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees749
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS6700024010
Valuation
P/E (Trailing)
P/E (Forward)-16.55
PEG1.32
EV/EBITDA16.48
EV/Revenue1.65
P/S2.48
P/B-11.42
EPS (TTM)-0.56
EPS (Forward)-0.54
52W Range
6.13073% of range11.97
52W High11.97 USD
52W Low6.130 USD
Profitability
Gross Margin93.50%
Oper. Margin-7.19%
EBITDA Margin9.98%
Profit Margin39.19%
ROE-344.65%
ROA37.42%
Growth
Revenue Growth-79.10%
Earnings Growth
Cash Flow & Leverage
Operating CF-244.63M USD
CapEx (TTM)6.39M USD
FCF Margin9.82%
FCF Yield3.43%
Net Debt-495.27M USD
Net Debt/EBITDA-8.32
Balance Sheet
Debt/Equity-1.95
Current Ratio2.48
Quick Ratio2.38
Book Value/Sh-0.7860 USD
Cash/Share4.806 USD
Dividends
Fwd Div Rate
Trail. Div Rate0.0000 USD
Div. Yield
5Y Avg Yield
Payout Ratio0.00%
Ex-Div Date
Pay DateMay 10, 2019
Splits
Last Split1:20
Split DateMay 10, 2019
Analyst Consensus
Rating2.3 (Buy)
Target (Mean)14.11 USD
Target Range7.000 USD25.00 USD
# Analysts9
Ownership
Shares Out.164.44M
Float141.47M
Insiders5.01%
Institutions69.56%
Short Interest
Short Ratio15.6d
Short % Float30.28%
Short % Out.30.09%
Shares Short49.48M
Short (prev mo.)44.99M
Technical
SMA 508.832 (+17.7%)
SMA 2008.339 (+24.7%)
Beta2.37
S&P 52W Chg28.31%
Avg Vol (30d)4.84M
Avg Vol (10d)6.00M
Technical Indicators
RSI (14)
MACD
MACD Signal
MACD Hist.
BB Upper
BB Middle
BB Lower
BB Width
ATR (14)
Vol Ratio (20d)